Scancell Holdings PLC
F:SCP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Scancell Holdings PLC (SCP) under the Base Case is 0.231 EUR per share.
Compared with the current market price of 0.917 EUR, the stock appears
Overvalued by 75% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Scancell Does
Scancell Holdings is a UK biotechnology company focused on making new cancer treatments, especially immunotherapies that help the body’s immune system find and attack tumors. Its main work is developing drug candidates in the lab and through clinical trials rather than selling finished medicines today. The company is built around a small number of proprietary platforms, including programs aimed at cancer and some infectious disease targets.
- Headquarters
- United Kingdom UK
- Employees
- 60
- IPO date
- Jul 30, 2010
Continue SCP Research
Decided on Scancell Holdings? Get an email when SCP reaches the price you’d buy at. Free with an account.
Other Scancell Holdings listings
What is the Intrinsic Value of one SCP stock?
The intrinsic value for
Scancell Holdings PLC (SCP) under the Base Case is 0.231 EUR.
Is SCP stock undervalued or overvalued?
Compared with the current market price of 0.917 EUR, the stock appears Overvalued by 75% .